News

The need for biopharma companies to equip data managers with the training and resources necessary to capitalize on new digital health tools.

Breaking down the evolving role of today’s clinical data manager-and its importance as a key cog in the clinical research ecosystem of tomorrow.

Tzvia Bader, CEO of TrialJectory, discusses how the company’s AI-powered technology platform is democratizing cancer care and expanding access to advanced new treatments.

With the Coronavirus causing significant disruptions in the clinical trials industry, Sponsors should expect data quality issues due to missed visits and a reduction in enrollment rates.

Though on its way out of the European Union, the UK is trying to align its trial approval practice with the EU’s new clinical trial regulation.

Ravi Jandhyala, Consultant Pharmaceutical Physician at Medialis and an expert in rare disease patient registries, discusses how to overcome clinical trial registry challenges.

With radio, billboard, TV, and digital advertisements being left in the dust, additional engagement from influencer communities are more likely to be reach patients.

Allyson Gage, Chief Medical Officer at Cohen Veterans Bioscience talks about her perspectives on platform trial design.

A case study of the risk-based quality management learning curve.

Click the title above to open the Applied Clinical Trials March 2020 issue in an interactive PDF format.

The trends that seem to be garnering the most discussion today among clinical trial management and operations professionals.

Teenagers with cancer could benefit from a proposed initiative to lower the age barrier for participation in trials for new oncology drugs.

A compilation of recently released news briefs that pertain to the clinical trials industry.

Study holds new benchmarks and improvement opportunities.

Jennifer Bradford, head of data science for Phastar, shares data and analytics-related learnings from a diverse career journey in research

With the final approval and release of ICH E9 (R1), clinical trial sponsors should prepare to include estimands in their protocols as well as their statistical design documents and study reports.